What is the recommended work‑up for a 38‑year‑old Asian male with hypertension on perindopril, elevated low‑density lipoprotein cholesterol, triglycerides, apolipoprotein B, a urine albumin‑creatinine ratio of 4.86 mg/mmol (confirmed twice), and HbA1c of 5.6%?

Comprehensive Cardiovascular and Metabolic Work-Up Required

This 38-year-old Asian male with multiple cardiovascular risk factors requires immediate evaluation for metabolic syndrome, secondary causes of hypertension, and comprehensive cardiovascular risk stratification, with consideration for intensified lipid-lowering therapy given his markedly elevated apolipoprotein B and LDL-C levels.

Immediate Laboratory Assessment

Metabolic and Diabetes Screening

• Fasting glucose and 2-hour oral glucose tolerance test (OGTT): While his HbA1c of 5.6% is below the diabetes threshold, this patient has multiple features suggesting insulin resistance (hypertriglyceridemia, low-normal HDL, elevated ApoB). Asian populations develop diabetes at lower BMI thresholds, and OGTT may reveal impaired glucose tolerance not captured by HbA1c alone 1.

• Fasting insulin and HOMA-IR calculation: To quantify insulin resistance, which is strongly associated with his lipid profile pattern 2.

Renal Function Assessment

• Serum creatinine and eGFR: Essential baseline given his albuminuria (ACR 4.86 mg/mmol, confirmed twice) and use of perindopril 1, 3.

• Serum potassium: Must be monitored at least annually in patients on ACE inhibitors, particularly with any degree of renal dysfunction 4, 1, 3. Initial baseline is critical.

• Complete urinalysis with microscopy: To evaluate for other causes of albuminuria and assess for diabetic kidney disease markers 1.

Lipid and Cardiovascular Markers

• Lipoprotein(a) [Lp(a)]: Single measurement recommended, as elevated Lp(a) ≥50 mg/dL constitutes a risk-enhancing factor, particularly relevant given his family risk profile and Asian ethnicity 5.

• High-sensitivity C-reactive protein (hs-CRP): If ≥2.0 mg/L, this constitutes an additional risk-enhancing factor for treatment decisions 5.

• Repeat fasting lipid panel: To confirm the severe dyslipidemia pattern (LDL-C 4.4 mmol/L [170 mg/dL], triglycerides 3.84 mmol/L [340 mg/dL], ApoB 1.44 g/L [144 mg/dL]) 5.

Secondary Hypertension Screening

Given his young age (38 years) and hypertension requiring treatment:

• Thyroid-stimulating hormone (TSH): Hypothyroidism can cause both hypertension and hyperlipidemia 6.

• Morning cortisol and/or 24-hour urinary free cortisol: Screen for Cushing's syndrome, which presents with hypertension, metabolic syndrome features, and dyslipidemia.

• Plasma aldosterone concentration (PAC) and plasma renin activity (PRA): Calculate aldosterone-renin ratio to screen for primary aldosteronism, particularly if hypertension proves difficult to control 4, 7.

• Renal artery duplex ultrasound or CT angiography: Consider if clinical suspicion for renovascular hypertension exists, though less likely given stable ACR.

Cardiovascular Risk Stratification

Imaging Studies

• Coronary artery calcium (CAC) score: Strongly recommended for this intermediate-risk patient to guide intensity of lipid-lowering therapy. A CAC score of zero might allow for shared decision-making regarding statin intensity, while any detectable calcium would mandate aggressive treatment 5.

• Carotid intima-media thickness (CIMT) or ankle-brachial index (ABI): If ABI <0.9, this constitutes a risk-enhancing factor. Consider if CAC scoring unavailable 5.

• Echocardiogram: To assess for left ventricular hypertrophy (target organ damage from hypertension) and baseline cardiac function 1.

Electrocardiogram

• 12-lead ECG: Screen for left ventricular hypertrophy, conduction abnormalities, or silent ischemia 1.

Critical Lipid Profile Interpretation

This patient demonstrates severe discordance between LDL-C and triglycerides with markedly elevated ApoB (144 mg/dL, well above the 130 mg/dL risk-enhancing threshold). This pattern indicates:

1. High particle number despite "moderate" LDL-C: ApoB of 144 mg/dL indicates approximately 144 million atherogenic particles per deciliter, which is severely elevated 5, 2.

2. Metabolic syndrome features: The combination of hypertriglyceridemia (3.84 mmol/L), relatively low HDL-C (1.7 mmol/L is borderline), elevated ApoB, and borderline HbA1c strongly suggests metabolic syndrome 5, 2.

3. Increased CKD risk: Discordantly high ApoB with this lipid pattern is independently associated with chronic kidney disease progression, which may explain his persistent albuminuria 2.

Monitoring Parameters

Baseline Before Treatment Intensification

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST): Required before initiating or intensifying statin therapy 6.

• Creatine kinase (CK): Baseline measurement useful for comparison if myalgias develop 6.

Ongoing Monitoring Schedule

• Serum creatinine/eGFR and potassium: At least annually, more frequently if eGFR declines or with medication changes 4, 1, 3.

• Urine albumin-creatinine ratio: Every 6-12 months to monitor progression and treatment response 1.

• HbA1c: Every 6 months given his prediabetic state 1.

• Lipid panel: 4-12 weeks after statin initiation or dose change, then annually once stable 8.

Blood Pressure Management Considerations

His current perindopril monotherapy is appropriate as first-line treatment given his albuminuria (ACR 4.86 mg/mmol, equivalent to approximately 43 mg/g), as ACE inhibitors are recommended for patients with UACR 30-299 mg/g 1, 3, 9. However:

• Confirm blood pressure control: Obtain home blood pressure readings or 24-hour ambulatory monitoring to ensure target <130/80 mmHg is achieved 1.

• Anticipate need for additional agents: Multiple-drug therapy is generally required to achieve BP goals, particularly with metabolic syndrome 1, 9. If BP remains elevated, add a thiazide-like diuretic (chlorthalidone or indapamide preferred) or dihydropyridine calcium channel blocker 1, 3, 9.

Common Pitfalls to Avoid

1. Do not rely solely on LDL-C: His ApoB of 144 mg/dL indicates far greater cardiovascular risk than his LDL-C of 4.4 mmol/L suggests. ApoB is the superior predictor when discordant 2.

2. Do not overlook Asian-specific risk: Asian populations have higher cardiovascular risk at lower traditional thresholds and develop diabetes at lower BMI 1.

3. Do not dismiss "mild" albuminuria: Even at this level (4.86 mg/mmol), confirmed on two occasions, this indicates early kidney disease and significantly elevated cardiovascular risk 1, 3.

4. Monitor for hyperkalemia vigilantly: ACE inhibitors with concurrent metabolic dysfunction increase hyperkalemia risk. This becomes critical if additional RAAS blockade or mineralocorticoid receptor antagonists are considered 4, 7, 10.

5. Do not delay statin therapy: With ApoB >130 mg/dL, LDL-C >4.0 mmol/L, hypertension, and albuminuria, this patient requires high-intensity statin therapy regardless of calculated 10-year risk 5.